Aleksei Vorobev

Mr. Aleksei Vorobev

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
NANataliia P. Antonova
Nataliia P. Antonova
DVDaria V. Vasina
Daria V. Vasina
IGIgor Grigoriev
Igor Grigoriev
ALAleksei I. Laishevtsev
Aleksei I. Laishevtsev
AKAndrey V. Kapustin
Andrey V. Kapustin
Vladimir GushchinVladimir Gushchin
Vladimir Gushchin

29 April 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
NANataliia P. Antonova
Nataliia P. Antonova
DVDaria V. Vasina
Daria V. Vasina
IGIgor V. Grigoriev
Igor V. Grigoriev
EUEvgeny Usachev
Evgeny Usachev
AAAndrey V. Aleshkin
Andrey V. Aleshkin
VGVladimir A. Gushchin
Vladimir A. Gushchin

16 October 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
DVDaria V. Vasina
Daria V. Vasina
NANataliia P. Antonova
Nataliia P. Antonova
AVAleksei Vorobev
Aleksei Vorobev
ALAlexey Laishevtcev
Alexey Laishevtcev
AKAndrei Kapustin
Andrei Kapustin
Vladimir GushchinVladimir Gushchin
Vladimir Gushchin
Abscess formation is a common complication of severe life-threatening infections caused by obligate anaerobes. Fusobacterium necrophorum is among the frequently detected anaerobic pathogens from clinical specimens associated with liver abscesses, skin and soft tissue infections, or oral abscesses. The antimicrobial therapy for this kind of infection needs to be optimized. Here, we examined the possibility of treating F. necrophorum-induced abscess wound infections with candidate therapeutics based on three endolysins with activity against a broad spectrum of aerobe Gram-negative pathogens. Antibacterial gel containing three Gram-negative bacteria-targeting endolysins, LysAm24, LysAp22, and LysECD7, was formulated for topical use. Abscess formation was induced in rabbits with F. necrophorum and caused systemic infection. The survival and lifespan of the animals, general parameters, and biochemical and hematological blood tests were analyzed to assess the effectiveness of the gel treatment for the wound infection. The administration of the investigated gel twice per day for 5 days resulted in less acute inflammation, with decreased leukocytes and segmented neutrophils in the blood, retardation of infection progression, and an almost two-fold increase in the lifespan of the animals compared to the placebo group. The results indicate that endolysin-based therapy is an effective approach to treat anaerobic bacterial infections. The use of endolysins as independent pharmaceuticals, or their combination with antibiotics, could significantly reduce the development of complications in infectious diseases caused by sensitive bacterial species.

29 May 2022 in Drug development & registration
Verified
Journal Article
Open access
PDF file
EBElena Bakhrushina
Elena Bakhrushina
MAM. N. Anurova
M. N. Anurova
SBS. S. Bochkareva
S. S. Bochkareva
AVAleksei Vorobev
Aleksei Vorobev
YSYu. O. Shcherbina
Yu. O. Shcherbina
ЮЩЮ. О. Щербина
Ю. О. Щербина
Introduction. Infectious otitis externa and middle ear can cause hearing loss, which significantly reduces the quality of life of patients. The main causative agents of acute bacterial otitis media are Pseudomonas aeruginosa and Staphylococcus aureus. This article is devoted to the development and study of a novel dosage form for treatment of infectious diseases of the external ear containing bacteriophages that lyse bacterial strains of Pseudomonas aeruginosa. Ear drops were considered as a promising dosage form for instillation into the ear canal.Aim. The aim of the work is to develop a dosage form of Pseudomonas aeruginosa bacteriophages for the local treatment of infectious otitis media.Materials and Methods. The active substances of the developed drug are bacteriophages that lyse bacterial strains of Pseudomonas aeruginosa: PA5 and PA10, which were obtained by growing on a solid growth medium in mattress flasks with subsequent sterilizing filtration through a membrane filter (0,22 µm) and elimination of endotoxins on a chromatographic column. To obtain experimental compositions, excipients that do not cause a drop in the titer of bacteriophages were used – purified water as the solvent, viscosity modifiers: glycerol (CHIMMED, Russia) and a mix of macrogol 6 and glyceryl caprilocaprate brand Softigen 767 (Cremer, Germany), antioxidant Ethylenediaminetetraacetic acid (EDTA), preservatives nipagin and nipazole. The obtained samples were standardized according to pharmacopoeial indicators, recommended for the dosage form "drops" – density, pH, viscosity. For all experimental compositions, the stability of the titer of bacteriophages was studied by the Gratia method for 6 months. The local irritation and systemic effects were also studied on five chinchilla male rabbits.Results and discussion. As a result of the conducted research, four experimental compositions of ear drops with a cocktail of bacteriophages PA5 and PA10 were obtained. The optimal technological characteristics were observed in the composition containing glycerol as a viscosity modifier at a concentration of 10,0 %. For optimal composition, the stability of the bacteriophages cocktail titer, local irritating and systemic effects were analyzed. The study revealed stability of the bacteriophages PA5 and PA10 titers in the composition of dosage form, and absence of local irritating and systemic effects of ear drops.Conclusion. The dosage form can be recommended for preclinical studies.

31 March 2021 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
AVAleksei Vorobev
Aleksei Vorobev
MAM. N. Anurova
M. N. Anurova
AAA. V. Aleshkin
A. V. Aleshkin
Vladimir GushchinVladimir Gushchin
Vladimir Gushchin
DVD. V. Vasina
D. V. Vasina
AKAlexander Karaulov
Alexander Karaulov

1 January 2021 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
AAA. V. Aleshkin
A. V. Aleshkin
LNL. I. Novikova
L. I. Novikova
SBS. S. Bochkareva
S. S. Bochkareva
SKS. Iu. Kombarova
S. Iu. Kombarova
ILIu. S. Lebedin
Iu. S. Lebedin
LCLtd. Xema Co.
Ltd. Xema Co.